These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 26446253

  • 1. Gender Differences in the Efficacy and Safety of Chronic Nightly Zolpidem.
    Roehrs TA, Roth T.
    J Clin Sleep Med; 2016 Mar; 12(3):319-25. PubMed ID: 26446253
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.
    Roehrs TA, Randall S, Harris E, Maan R, Roth T.
    J Psychopharmacol; 2012 Aug; 26(8):1088-95. PubMed ID: 22004689
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T, Soubrane C, Titeux L, Walsh JK, Zoladult Study Group.
    Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
    Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M.
    JAMA Netw Open; 2019 Dec 02; 2(12):e1918254. PubMed ID: 31880796
    [Abstract] [Full Text] [Related]

  • 7. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
    Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T, ZOLONG Study Group.
    Sleep; 2008 Jan 02; 31(1):79-90. PubMed ID: 18220081
    [Abstract] [Full Text] [Related]

  • 8. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia.
    Erman MK, Zammit G, Rubens R, Schaefer K, Wessel T, Amato D, Caron J, Walsh JK.
    J Clin Sleep Med; 2008 Jun 15; 4(3):229-34. PubMed ID: 18595435
    [Abstract] [Full Text] [Related]

  • 9. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia.
    Perlis ML, McCall WV, Krystal AD, Walsh JK.
    J Clin Psychiatry; 2004 Aug 15; 65(8):1128-37. PubMed ID: 15323600
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial.
    Maroo N, Hazra A, Das T.
    Indian J Pharmacol; 2013 Aug 15; 45(1):34-9. PubMed ID: 23543804
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo.
    Roth T, Roehrs T, Vogel G.
    Sleep; 1995 May 15; 18(4):246-51. PubMed ID: 7618022
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.